TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Serina Therapeutics ( (SER) ) is now available.
On September 9, 2025, Serina Therapeutics entered into a $20 million unsecured convertible note agreement with board member Gregory H. Bailey, M.D. The funding, structured in five tranches, is tied to clinical and operational milestones, supporting the company’s SER-252-1b clinical study. This financial arrangement strengthens Serina’s operational capabilities and positions it strategically within the biotechnology sector. The agreement includes provisions for interest, conversion into common stock, and issuance of warrants, reflecting a significant step in the company’s growth and development plans.
The most recent analyst rating on (SER) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.
Spark’s Take on SER Stock
According to Spark, TipRanks’ AI Analyst, SER is a Neutral.
Serina Therapeutics’ overall stock score is significantly impacted by its poor financial performance, which is the most critical factor. The technical analysis also indicates a bearish trend, further contributing to the low score. The valuation is unfavorable due to a negative P/E ratio and lack of dividend yield. These factors collectively suggest high risk and potential instability.
To see Spark’s full report on SER stock, click here.
More about Serina Therapeutics
Serina Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of therapeutic products. The company is involved in clinical studies and is working on advancing its pipeline of drug candidates.
Average Trading Volume: 125,075
Technical Sentiment Signal: Sell
Current Market Cap: $53.2M
Find detailed analytics on SER stock on TipRanks’ Stock Analysis page.